Meeting
2021 ASCO Annual Meeting
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.
Authors
Hiroshi Takumida
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Hiroshi Takumida , Hidehito Horinouchi , Ken Masuda , Yuki Shinno , Yusuke Okuma , Tatsuya Yoshida , Yasushi Goto , Noboru Yamamoto , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9061)
DOI
10.1200/JCO.2021.39.15_suppl.9061
Abstract #
9061
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
First Author: Elizabeth Jimenez Aguilar
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
